[go: up one dir, main page]

WO2008099469A1 - 赤血球の脂質過酸化を抑制するための組成物および方法 - Google Patents

赤血球の脂質過酸化を抑制するための組成物および方法 Download PDF

Info

Publication number
WO2008099469A1
WO2008099469A1 PCT/JP2007/052588 JP2007052588W WO2008099469A1 WO 2008099469 A1 WO2008099469 A1 WO 2008099469A1 JP 2007052588 W JP2007052588 W JP 2007052588W WO 2008099469 A1 WO2008099469 A1 WO 2008099469A1
Authority
WO
WIPO (PCT)
Prior art keywords
erythrocytes
composition
lipid peroxidation
suppressing lipid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/052588
Other languages
English (en)
French (fr)
Inventor
Teruo Miyazawa
Kiyotaka Nakagawa
Jun Kariya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Project M Co Ltd
Original Assignee
Tohoku University NUC
Project M Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Project M Co Ltd filed Critical Tohoku University NUC
Priority to PCT/JP2007/052588 priority Critical patent/WO2008099469A1/ja
Priority to US12/527,166 priority patent/US20100076091A1/en
Priority to JP2008557927A priority patent/JPWO2008099469A1/ja
Priority to EP07714141A priority patent/EP2123263A1/en
Publication of WO2008099469A1 publication Critical patent/WO2008099469A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　本発明は、キサントフィルまたはそのエステルを有効成分として含む、赤血球の脂質過酸化を抑制するための組成物および認知症を予防または治療するための組成物、ならびに哺乳動物の赤血球におけるキサントフィルまたはそのエステルの濃度を測定することを含む、認知症の診断方法に関する。
PCT/JP2007/052588 2007-02-14 2007-02-14 赤血球の脂質過酸化を抑制するための組成物および方法 Ceased WO2008099469A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/JP2007/052588 WO2008099469A1 (ja) 2007-02-14 2007-02-14 赤血球の脂質過酸化を抑制するための組成物および方法
US12/527,166 US20100076091A1 (en) 2007-02-14 2007-02-14 Composition and method for suppressing lipooxidation of erythrocyte
JP2008557927A JPWO2008099469A1 (ja) 2007-02-14 2007-02-14 赤血球の脂質過酸化を抑制するための組成物および方法
EP07714141A EP2123263A1 (en) 2007-02-14 2007-02-14 Composition and method for suppressing lipid peroxidation in erythrocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/052588 WO2008099469A1 (ja) 2007-02-14 2007-02-14 赤血球の脂質過酸化を抑制するための組成物および方法

Publications (1)

Publication Number Publication Date
WO2008099469A1 true WO2008099469A1 (ja) 2008-08-21

Family

ID=39689728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/052588 Ceased WO2008099469A1 (ja) 2007-02-14 2007-02-14 赤血球の脂質過酸化を抑制するための組成物および方法

Country Status (4)

Country Link
US (1) US20100076091A1 (ja)
EP (1) EP2123263A1 (ja)
JP (1) JPWO2008099469A1 (ja)
WO (1) WO2008099469A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037768A (ja) * 2009-08-11 2011-02-24 Hideyasu Hirano 赤血球変形能改善剤
JP2013510129A (ja) * 2009-11-09 2013-03-21 ディーエスエム アイピー アセッツ ビー．ブイ． 記憶の一部側面を増強するためのルテイン含有組成物の使用
JP2013510076A (ja) * 2009-09-11 2013-03-21 ネステク ソシエテ アノニム 動物の認知機能及び認知関連機能を向上させるための組成物及び方法
WO2016035790A1 (ja) * 2014-09-01 2016-03-10 グリコ栄養食品株式会社 赤血球機能向上剤
JP6025568B2 (ja) * 2010-12-28 2016-11-16 株式会社藤野ブレインリサーチ 認知症を血液サンプルで判定するための検査方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210662A (zh) * 2010-04-06 2011-10-12 北京联合大学应用文理学院 叶黄素在制备防治脑血管疾病药物中的应用
CA2907886A1 (en) * 2013-03-28 2014-10-02 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892205A (ja) * 1994-03-17 1996-04-09 Univ America Catholic ケン化したマリゴールドの含油樹脂からのルテインの単離、精製および再結晶法、およびその使用
JP2001002569A (ja) * 1999-06-18 2001-01-09 Itano Refrigerated Food Co Ltd 記憶力改善組成物
JP2002513411A (ja) * 1997-04-04 2002-05-08 ヘンケル コーポレーション 高いバイオアベイラビリティを有するルテインエステル
JP2002226368A (ja) * 2001-02-02 2002-08-14 Fuji Chem Ind Co Ltd 赤血球の酸化的損傷抑制剤
JP2002535364A (ja) * 1999-01-29 2002-10-22 マーズ ユー ケー リミテッド ペット用動物のための抗酸化剤組成物およびその使用方法
JP2004059438A (ja) * 2002-07-25 2004-02-26 Bio Oriented Technol Res Advancement Inst 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
JP2004514686A (ja) * 2000-10-31 2004-05-20 コルゲート・パーモリブ・カンパニー 組成物と方法
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4630694B2 (ja) * 2005-03-07 2011-02-09 キヤノン株式会社 画像形成方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892205A (ja) * 1994-03-17 1996-04-09 Univ America Catholic ケン化したマリゴールドの含油樹脂からのルテインの単離、精製および再結晶法、およびその使用
JP2002513411A (ja) * 1997-04-04 2002-05-08 ヘンケル コーポレーション 高いバイオアベイラビリティを有するルテインエステル
JP2002535364A (ja) * 1999-01-29 2002-10-22 マーズ ユー ケー リミテッド ペット用動物のための抗酸化剤組成物およびその使用方法
JP2001002569A (ja) * 1999-06-18 2001-01-09 Itano Refrigerated Food Co Ltd 記憶力改善組成物
JP2004514686A (ja) * 2000-10-31 2004-05-20 コルゲート・パーモリブ・カンパニー 組成物と方法
JP2002226368A (ja) * 2001-02-02 2002-08-14 Fuji Chem Ind Co Ltd 赤血球の酸化的損傷抑制剤
JP2004059438A (ja) * 2002-07-25 2004-02-26 Bio Oriented Technol Res Advancement Inst 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037768A (ja) * 2009-08-11 2011-02-24 Hideyasu Hirano 赤血球変形能改善剤
JP2013510076A (ja) * 2009-09-11 2013-03-21 ネステク ソシエテ アノニム 動物の認知機能及び認知関連機能を向上させるための組成物及び方法
JP2013510129A (ja) * 2009-11-09 2013-03-21 ディーエスエム アイピー アセッツ ビー．ブイ． 記憶の一部側面を増強するためのルテイン含有組成物の使用
JP6025568B2 (ja) * 2010-12-28 2016-11-16 株式会社藤野ブレインリサーチ 認知症を血液サンプルで判定するための検査方法
WO2016035790A1 (ja) * 2014-09-01 2016-03-10 グリコ栄養食品株式会社 赤血球機能向上剤
JPWO2016035790A1 (ja) * 2014-09-01 2017-04-27 グリコ栄養食品株式会社 赤血球機能向上剤
JP2017122096A (ja) * 2014-09-01 2017-07-13 グリコ栄養食品株式会社 赤血球機能向上剤

Also Published As

Publication number Publication date
EP2123263A1 (en) 2009-11-25
JPWO2008099469A1 (ja) 2010-05-27
US20100076091A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2007089665A3 (en) Storage-stable cellular whole blood composition containing elevated amounts of d-dimer
WO2009105294A3 (en) Topical compositions and methods for whitening skin
WO2007109804A3 (en) Extracts and methods comprising cinnamon species
WO2008099469A1 (ja) 赤血球の脂質過酸化を抑制するための組成物および方法
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008017346A3 (de) Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2008112939A3 (en) Composition and method for making oligo-benzamide compounds
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP2149361A4 (en) OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2010126753A3 (en) Methods for improving taste and oral care compositions with improved taste
WO2006105306A3 (en) Compostions containing fatty acids and/or derivatives thereof and a low temperature stabilizer
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2008011272A3 (en) Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
WO2008132021A3 (de) Fungizide mischungen
WO2010027863A3 (en) Potentiated biocidal compositions and methods of use
WO2009102707A3 (en) Substituted oxazaphosphorines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07714141

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008557927

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12527166

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007714141

Country of ref document: EP